NINTH SUPPLEMENTAL INDENTURENinth Supplemental Indenture • April 12th, 2023 • Amryt Pharma PLC • Pharmaceutical preparations • New York
This NINTH SUPPLEMENTAL INDENTURE, dated as of April 12, 2023 (this “Supplemental Indenture”), is made and entered into by Amryt Pharmaceuticals, Inc. (f/k/a Aegerion Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), Amryt Pharma plc (f/k/a Amryt Pharma Holdings plc), a company incorporated in England and Wales with company number 12107859 (the “Parent”), the other guarantors party hereto (together with the Parent, the “Guarantors”), Chiesi Farmaceutici S.P.A., an Italian società per azioni (“Purchaser”), and GLAS Trust Company LLC, a limited liability company organized and existing under the laws of the State of New Hampshire, as trustee (in such capacity, the “Trustee”). Capitalized terms used herein and not otherwise defined have the meanings set forth in the Indenture referred to below.
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • April 12th, 2023 • Amryt Pharma PLC • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of April 12, 2023 (this “Agreement”), is entered into by and between Chiesi Farmaceutici S.p.A., an Italian società per azioni (“Purchaser”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (together with Computershare, the “Rights Agent”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Transaction Agreement (as defined below).
